Beyond P-Values: How EFSA assesses biological relevance in nutraceutical trials
- EFSA prioritizes biological relevance over statistical significance, requiring meaningful, consistent, and reproducible health impacts for nutraceutical approval.
- Common pitfalls in trials include small effect sizes, short durations, and lack of dose-response data, leading to EFSA rejections.
